Ebola tops 800 cases; cancer data and a landmark quit-smoking ruling
Bundibugyo Ebola tops 800 cases; ASCO 2026 reshapes prostate and breast cancer care; FDA rules on cytisinicline today.
By Dr. Asher Knippel
Five stories define this week's health agenda: a widening Ebola emergency in Central Africa, two landmark phase 3 oncology trial readouts from ASCO 2026, a first-of-its-kind paediatric diabetes approval, and a US regulatory decision due today on the first new quit-smoking medicine in twenty years.
Ongoing: Bundibugyo Ebola Outbreak Surpasses 800 Confirmed Cases
The 2026 Central Africa Ebola epidemic, caused by Bundibugyo virus — a distinct ebolavirus species separate from the Zaire strain responsible for earlier outbreaks — is the most consequential acute global public health emergency of this period. As of 15 June, the Democratic Republic of the Congo's Ministry of Health reported 837 confirmed cases and 196 confirmed deaths, with 376 patients hospitalised in isolation units. Ituri Province accounts for 767 of those confirmed cases across 20 health zones; North Kivu has reported 67 more across 10 health zones; and Uganda has recorded cross-border cases.
WHO declared a Public Health Emergency of International Concern on 17 May. What makes this outbreak harder to control than the 2018–2020 Kivu crisis is the absence of any licensed vaccine or specific therapeutic for Bundibugyo virus — unlike for the Zaire species, where the rVSV-ZEBOV vaccine exists. ECDC assesses the risk to European residents as very low, but highlights elevated occupational risk for healthcare workers in affected zones. Complicating factors include ongoing armed conflict, population displacement, mining-related mobility, and frequent cross-border movement between DRC and Uganda. WHO and the EMA's management board are coordinating European support to the response, including surveillance, supply delivery, and community engagement.
Bundibugyo disease causes haemorrhagic fever with a historical case fatality rate of roughly 25–35%. Supportive care — aggressive rehydration, electrolyte correction, and treatment of secondary infections — is the primary clinical intervention. Travellers returning from affected provinces who develop fever, unexplained bleeding, or severe fatigue within the 21-day incubation period should contact health services immediately and disclose their travel history.
Week of 2 June – TALAPRO-3: A PARP Inhibitor Halves Prostate Cancer Progression Risk
Presented at the 2026 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine, the TALAPRO-3 phase 3 trial delivered meaningful results for men with metastatic castration-sensitive prostate cancer (mCSPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1 and BRCA2.
The trial randomised 599 patients to receive either talazoparib plus enzalutamide or placebo plus enzalutamide. Talazoparib is a PARP inhibitor — a class of drug that exploits cancer cells' inability to mend DNA strand breaks when an upstream repair pathway (HRR) is already defective. At a median follow-up of 37.6 months, the combination produced a 52% reduction in the risk of radiographic disease progression or death (hazard ratio 0.481, 95% CI 0.357–0.647). Benefit was most pronounced in BRCA-mutated patients specifically (hazard ratio 0.368 versus 0.567 for non-BRCA HRR alterations). Overall survival data remain immature but trend in favour of the combination, with 74 deaths in the treatment arm against 91 in the control arm.
Important context: the talazoparib arm saw more serious adverse events, a pattern consistent with other PARP inhibitor trials. Eligibility requires confirmed HRR gene alteration, so germline and somatic genetic testing is a prerequisite. Physicians managing patients with mCSPC who have not yet undergone HRR testing should consider referral. Regulatory submissions to the FDA and EMA based on these results are expected.
Friday, 12 June – FDA Approves Teplizumab for Newly Diagnosed Children with Stage 3 Type 1 Diabetes
On 12 June, the US Food and Drug Administration approved a new indication for Tzield (teplizumab-mzwv), Sanofi's immune-modulating monoclonal antibody, for children aged 8 to 17 who have been recently diagnosed with Stage 3 type 1 diabetes — the clinical stage at which blood glucose dysregulation is symptomatic and insulin therapy becomes necessary.
This is the first FDA-approved disease-modifying treatment for this age group at Stage 3. Teplizumab is an anti-CD3 monoclonal antibody that dampens the autoimmune T-cell attack on insulin-producing beta cells in the pancreas. It does not cure type 1 diabetes or eliminate the need for insulin; rather, by slowing the rate of immune-mediated beta-cell loss, it can extend the period of more manageable blood glucose control — easing the early burden of disease management for months to years. The approval was granted under the accelerated pathway, with C-peptide level preservation as a validated surrogate endpoint. Confirmatory post-market trials are ongoing.
A critical constraint: teplizumab must be initiated within six weeks of a Stage 3 diagnosis. This is a biological window, not an administrative one — the autoimmune process is most responsive to intervention in the earliest weeks following clinical onset. Paediatric diabetes centres should consider integrating rapid referral pathways for newly diagnosed children who may be candidates.
Saturday, 20 June – FDA Expected to Rule on Cytisinicline: First New Quit-Smoking Drug in 20 Years
Today is the Prescription Drug User Fee Act (PDUFA) target date for cytisinicline (Achieve Life Sciences), a partial agonist at nicotinic acetylcholine receptors being reviewed for smoking cessation in adults. If approved, it would mark the first new pharmacotherapy for nicotine dependence since varenicline (Chantix) received FDA clearance in 2006 — a two-decade gap in a therapeutic category with significant unmet need.
Cytisinicline is derived from cytisine, a plant alkaloid isolated from laburnum seeds that has been used as a quit-smoking aid under the brand name Tabex in Eastern Europe since the 1960s — but without the rigorous clinical-trial evidence base required for FDA approval. The ORCA-2 and ORCA-3 randomised trials, enrolling over 2,000 participants in total, demonstrated that cytisinicline produced statistically significant improvements in sustained smoking abstinence compared to placebo. The mechanism resembles varenicline's — partial receptor stimulation reduces withdrawal discomfort while diminishing the reinforcing effect of cigarettes — but the distinct pharmacological profile may carry a different tolerability and safety footprint. Tobacco smoking kills approximately eight million people per year globally according to WHO and remains the largest single preventable cause of premature death. A positive FDA decision today would give clinicians and patients a meaningful new option in a space that has had no new entrants in a generation.
ASCO 2026 – OPTIMA Trial: Genomic Test Identifies Breast Cancer Patients Who Can Skip Chemotherapy
Among the most immediately practice-changing results from ASCO 2026 is the OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) phase 3 trial, which shows that a validated genomic test can reliably identify patients with clinical high-risk early breast cancer who gain no meaningful benefit from adding chemotherapy to endocrine therapy.
The trial used the Prosigna (PAM50) 50-gene expression assay, which produces a risk-of-recurrence (ROR) score. In patients aged 40 and over with oestrogen receptor–positive, HER2-negative early breast cancer and a Prosigna ROR score of 60 or below, endocrine therapy alone proved non-inferior to chemotherapy plus endocrine therapy in terms of disease outcomes — with patients spared the well-documented toxicities of cytotoxic treatment: nausea, fatigue, alopecia, immune suppression, and increased infection risk. For patients with high genomic ROR scores, chemotherapy did retain benefit, confirming that the test stratifies meaningfully. Researchers estimate that approximately two-thirds of patients with clinical high-risk features but low genomic scores could safely forgo chemotherapy — translating to more than 5,000 NHS patients per year in the UK alone, and proportionally many more across global health systems. Clinicians treating this population should be aware of the Prosigna ROR threshold as a tool to support informed, shared decision-making with patients while awaiting formal clinical guideline integration.
The content of this article is intended for general journalistic and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Readers should consult a qualified clinician or specialist before making any changes to their treatment plan, medication regimen, or healthcare management.